APAC Kidney Cancer Therapeutics & Diagnostics Market, Market Segmented, by Cancer Type (Renal Cancer Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Other Cancer Types), By Therapeutic Class (Targeted Therapy and Immunotherapy), by Pharmacological Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2)), and by Diagnostics (Biopsy, Intravenous Pyelogram, CT Scan, Nephro-Ureteroscopy, Ultrasound, and Other Diagnostics)- Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138349
- Pages: 200
-
Format:
Report Overview
The APAC Kidney Cancer Therapeutics & Diagnostics Market, market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.1% during the forecast period
Kidney cancerbegins when healthy cells in 1 or bothkidneyschange and grow out of control, forming a mass called arenalcorticaltumor. Atumorcan be malignant, indolent, or benign. A malignanttumoris cancerous, meaning it can grow and spread to other parts of the body
Market Drivers
The major factors driving the growth of the market in the Asia region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Asia-Pacific kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period
1. APAC Kidney Cancer Therapeutics & Diagnostics Market Overview
A. Market Size
2. APAC Kidney Cancer Therapeutics & Diagnostics Growth Drivers
A. The rising number of kidney cancer cases
B. An increased R&D expenditure of the pharmaceutical companies
3. APAC Kidney Cancer Therapeutics & Diagnostics Market Segmentation
A. By Cancer Type
I. Renal Cancer Carcinoma
II. Clear Cell Renal Cell Carcinoma
III. Papillary Renal Cell Carcinoma
IV. Chromophobe Renal Cell Carcinoma
V. Other Cancer Types
B. By Therapeutic Class
I. Targeted Therapy
II. Immunotherapy
C. By Pharma logical Class
I. Angiogenesis Inhibitors
II. Monoclonal Antibodies
III. mTOR Inhibitors
IV. Cytokine Immunotherapy (IL-2)
D. By Diagnostic
I. Biopsy
II. Intravenous Pyelogram
III. CT Scan
IV. Nephro-Ureteroscopy
V. Ultrasound
VI. Other Diagnostics
4. Kidney Cancer Therapeutics & Diagnostics Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Novartis AG, Company overview, Product & Services, Strategies & Financials
B. Pfizer, Inc., Company overview, Product & Services, Strategies & Financials
C. F. Hoffmann-La Roche, Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Potential Growth Opportunities
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
